Structural modification of H histo-blood group antigen.

Wei Zhang, Ziyan ZhuPubMed 2015 · DOI

Abstract

ABO blood group polymorphisms are determined by A, B, or H antigens. H substance is a precursor converted into A or B antigens; its presence is characteristic of blood group O. This study explores the enzymatic modification of H antigens on human erythrocytes using $\alpha$-1,2-L-fucosidase and N-acetylgalactosaminyltransferase (A-transferase) to create "Enzyme-Converted group O Red Blood Cells" (ECO-RBC). While Type 2 H chains were successfully modified, Type 3 chains showed resistance, likely due to steric hindrance.

Introduction

Blood transfusions require precise ABO matching. The H antigen is the core precursor for A and B antigens. Individuals with the rare "Bombay" phenotype lack the H antigen entirely and produce anti-H antibodies, making them incompatible with standard type O blood. This research investigates the feasibility of using enzymes to "strip" or modify H antigens on red blood cells (erythrocytes) to mimic the Bombay phenotype or create universal donor units. Specifically, the study examines how different structural "flavors" of the H antigen—Type 2 and Type 3 chains—respond to enzymatic treatment.

Methods

Red blood cells from healthy donors (A1, A2, B, and O) were sourced from the Shanghai Blood Centre, with Para-Bombay cells serving as a critical negative control. Two enzymatic strategies were employed:

  1. Cleaving: $\alpha$-1,2-L-fucosidase was used to remove the terminal L-fucose residue from the H antigen. Optimal conditions were tested across a pH range of 5.6 to 6.9 and incubation times of 1 to 4 hours.
  2. Transferring: Plasma-derived A-transferase was used to attempt the conversion of H antigens into A antigens, specifically targeting Type 3 chains.

Verification was performed using Flow Cytometry (FACS) with monoclonal antibodies like MBr1 and DG gel neutral analysis for antigen detection. Cellular integrity was assessed via Scanning Electron Microscopy (SEM) and membrane potential measurements.

Figure 1: Optimization of enzymatic treatment showing pH sensitivity and time-course analysis of H antigen removal.

Results

pH and Time Sensitivity

The $\alpha$-1,2-L-fucosidase enzyme exhibited maximum activity at an acidic pH (5.6–6.0). As shown in Figure 1, the enzyme's efficiency in stripping fucose decreased significantly as the environment became more neutral (pH 6.9). Complete removal of Type 2 H antigens from A1, A2, B, and O cells was achieved after 4 hours of treatment at pH 5.6, resulting in what the authors term "FM-erythrocytes."

Cellular Integrity and Safety

The enzymatic treatment was remarkably specific, leaving other major blood group systems (Rh, MNS, Kell, Duffy, and Kidd) untouched. SEM imaging confirmed that the treated FM-erythrocytes maintained their characteristic biconcave shape (Figure 3). While a slight decrease in absolute membrane potential was observed, this was determined to be a side effect of the acidic buffer rather than the loss of the fucose sugar itself.

Figure 3: Assessment of cellular integrity through membrane potential analysis (A), light microscopy (B), and SEM (C), alongside flow cytometry (D).

Structural Resistance of Type 3 Chains

A critical finding was the resistance of Type 3 H antigens to enzymatic modification. Despite prolonged incubation with A-transferase, Type 3 chains on A1 and A2 cells remained detectable. This resistance is hypothesized to stem from "steric hindrance," where the complex, branched structure of Type 3 chains physically blocks the enzyme's access to the target fucose residue.

Discussion

The study demonstrates the successful enzymatic removal of the predominant Type 2 H antigens, moving closer to the goal of universal donor blood. However, the persistence of Type 3 and Type 4 chains presents a significant hurdle. Because these structures remain intact, the modified cells do not perfectly replicate the Bombay phenotype and might still trigger immune responses in sensitized recipients. Future research must focus on engineering glycosidases capable of overcoming steric hindrance to ensure complete antigen removal. Scaling these laboratory successes into transfusion-ready clinical products remains a major technical and regulatory challenge.

Summary updated

Abstract

ABO blood group polymorphisms of humans and other primates are determined by the expression of A, B, or H antigens, which are terminal neutral glycan sequences that are abundant in glycoproteins and glycolipids. H substance is a precursor which, under the influence of genes A and B, is converted into blood group substance A or B, respectively. Given that the inactive O allele does not alter H substance, the presence of unchanged H determinants is characteristic of blood group O individuals. ABH blood group antigens in human erythrocyte membranes occur as glycolipids and glycoproteins. Among blood group ABH glycolipids on erythrocytes, substances with type 2 chains are predominant. Glycolipids with type 3 and 4 chains are present only in insignificant amounts and type 1 chain glycolipids are adsorbed from the plasma because they are not endogenous erythrocyte substances. Blood group H active antigens have been found on O-linked and N-linked carbohydrate chains1–3. The H-specific oligosaccharide unit has been identified as the trisaccharide Fucα1-2Galβ1-3GalNAc-. In the majority of these H chains, N-acetylgalactosamine carries an α2-6 neuraminic acid residue, but this structure does not seem to have any serological activity4. The blood group H determinant in human erythrocytes is carried mainly by a lacto-series type 2 chain5. Type 3 chain glycolipids have been found only in group A erythrocytes. Type 3 substance is characteristic of group A1 erythrocytes and is present in only trace amounts in A2 cells. Precursor H type 3 occurs in greater quantities in A2 erythrocytes than in A1 erythrocytes, but is absent in O and B cells. As early as the mid-20th century, studies showed that some micro-organisms have enzymatic activities that can modify ABO type6. However, it was not until the 1980s that the pioneering work of Goldstein and Lenny (New York Blood Center, NY, USA) discovered technology for enzymatic conversion of A and B antigens which could be used in blood transfusion7. The general name used for the technological concept is “Enzyme-Converted group O Red Blood Cells” (ECO-RBC). Based on the ECO-RBC concept, glycosidase and glycosyltransferase were used to modify the structure of blood group H antigens. α-1,2-L-fucosidase is a highly specific exoglycosidase that catalyses the hydrolysis of α1-2 linked L-fucopyranosyl residues from oligosaccharides, whereas plasma-derived N-acetylgalactosaminyltransferases (A-transferase) transfer N-acetylgalactosamine residues onto galactose residues in H determinants in the presence of UDP-N-acetylgalactosamine. In this study, we used α-1,2-L-fucosidase to modify the structure of type 2 chain H. The modified antigens did not show type 2 chain H antigen activity. The erythrocytes treated by fucosidase are called FM-erythrocytes. We used the A-transferase from A1 plasma to modify the structure of type 3 chain H antigens. The erythrocytes treated by A-transferase are called TM-erythrocytes.
BibTeX
@inproceedings{zhang2015structural,
  author = {Wei Zhang and Ziyan Zhu},
  title = {{Structural modification of H histo-blood group antigen.}},
  booktitle = {PubMed},
  year = {2015},
  doi = {10.2450/2014.0033-14},
}
Figure